Cerebrovascular disease in ageing and Alzheimer’s disease
Open Access
- 28 December 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Acta Neuropathologica
- Vol. 131 (5), 645-658
- https://doi.org/10.1007/s00401-015-1522-0
Abstract
Cerebrovascular disease (CVD) and Alzheimer’s disease (AD) have more in common than their association with ageing. They share risk factors and overlap neuropathologically. Most patients with AD have Aβ amyloid angiopathy and degenerative changes affecting capillaries, and many have ischaemic parenchymal abnormalities. Structural vascular disease contributes to the ischaemic abnormalities in some patients with AD. However, the stereotyped progression of hypoperfusion in this disease, affecting first the precuneus and cingulate gyrus, then the frontal and temporal cortex and lastly the occipital cortex, suggests that other factors are more important, particularly in early disease. Whilst demand for oxygen and glucose falls in late disease, functional MRI, near infrared spectroscopy to measure the saturation of haemoglobin by oxygen, and biochemical analysis of myelin proteins with differential susceptibility to reduced oxygenation have all shown that the reduction in blood flow in AD is primarily a problem of inadequate blood supply, not reduced metabolic demand. Increasing evidence points to non-structural vascular dysfunction rather than structural abnormalities of vessel walls as the main cause of cerebral hypoperfusion in AD. Several mediators are probably responsible. One that is emerging as a major contributor is the vasoconstrictor endothelin-1 (EDN1). Whilst there is clearly an additive component to the clinical and pathological effects of hypoperfusion and AD, experimental and clinical observations suggest that the disease processes also interact mechanistically at a cellular level in a manner that exacerbates both. The elucidation of some of the mechanisms responsible for hypoperfusion in AD and for the interactions between CVD and AD has led to the identification of several novel therapeutic approaches that have the potential to ameliorate ischaemic damage and slow the progression of neurodegenerative disease.Keywords
Funding Information
- Medical Research Council (MR/K015397/1)
- Alzheimer’s Research UK (UK ART-PG2011-1, ARUK-NCG2013A-3, ARUK-PG2015-11)
- British Heart Foundation
- BRACE (Bristol Research into Alzheimer's and Care of the Elderly)
This publication has 169 references indexed in Scilit:
- Atrial Fibrillation and Risk of Dementia: A Prospective Cohort StudyJournal of the American Geriatrics Society, 2011
- Pericytes Control Key Neurovascular Functions and Neuronal Phenotype in the Adult Brain and during Brain AgingNeuron, 2010
- Contribution of vascular pathology to the clinical expression of dementiaNeurobiology of Aging, 2010
- Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of aging cohortAnnals of Neurology, 2010
- Hypometabolism in Alzheimer-Affected Brain Regions in Cognitively Healthy Latino Individuals Carrying the Apolipoprotein E ε4 AlleleArchives of Neurology, 2010
- ASL Perfusion MRI Predicts Cognitive Decline and Conversion From MCI to DementiaAlzheimer Disease & Associated Disorders, 2010
- Contribution of Vascular Risk Factors to the Progression in Alzheimer DiseaseArchives of Neurology, 2009
- Effects of HNE‐modification induced by Aβ on neprilysin expression and activity in SH‐SY5Y cellsJournal of Neurochemistry, 2009
- Multivariate and Univariate Analysis of Continuous Arterial Spin Labeling Perfusion MRI in Alzheimer's DiseaseJournal of Cerebral Blood Flow & Metabolism, 2007
- Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.Proceedings of the National Academy of Sciences of the United States of America, 1993